DiaSorin S.p.A. : Close to a key resistance level
| Entry price | Target | Stop-loss | Potential |
|---|
|
€179.7 |
€204.38 |
€144.5 |
+13.73% |
|---|
DiaSorin S.p.A. shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
● The stock is in a well-established, long-term rising trend above the technical support level at 123.8 EUR
● The company's "enterprise value to sales" ratio is among the highest in the world.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.75 times its estimated earnings per share for the ongoing year.
● The company is not the most generous with respect to shareholders' compensation.
● The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
DIASORIN S.P.A. 
